

# Interim report 1 January – 31 March 2023

## Strong organic growth in both business areas

*"Strong organic growth of 12 percent this quarter reflects high demand for our products and services. We are well-positioned for the recovery that is now taking place in health care and is expected to continue for a long time to come."*  
Fredrik Dalborg, President and CEO


### 1 JANUARY – 31 MARCH 2023 (3 MONTHS)

- Net sales decreased by 5 percent to SEK 2,457m (2,579), partly driven by the fact that covid-19 related sales decreased to SEK 0m (510). Organic growth excluding covid-19 related turnover was 12 percent and acquired growth was 2 percent.
- EBITA amounted to SEK 366m (435), corresponding to an EBITA-margin of 14.9 percent (16.9). EBITA includes a reversed contingent consideration amounting to 83m, adjusted for this the EBITA-margin amounts to 11.5 percent.
- Profit after tax amounted to SEK 174m (225).
- Earnings per share amounted to SEK 1.43 (1.85). Earnings per share for the last 12 months amounted to SEK 3.54 (5.91).
- Cash flow from operating activities amounted to SEK 105m (332).
- The equity ratio was 39 percent (38).
- Return on working capital (P/WC) amounted to 55 percent (61).

**12 %**  
ORGANIC GROWTH  
Q1 2023

SEKm	3 months ending			12 months ending	
	31 Mar 23	31 Mar 22	change	31 Mar 23	31 Dec 22
Net sales	2,457	2,579	-5%	8,962	9,084
EBIT	258	338	-24%	728	808
EBITA	366	435	-16%	1,152	1,221
EBITA-margin	14.9%	16.9%		12.9%	13.4%
Profit before tax	206	289	-29%	519	602
Profit for the period	174	225	-23%	432	483
Earnings per share before dilution, SEK	1.43	1.85	-23%	3.54	3.96
Earnings per share after dilution, SEK	1.42	1.84	-23%	3.54	3.95

NET SALES (SEKM)



EBITA (SEKM)

